A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda

Tharcisse Mpunga, Ariana Znaor, F. Regis Uwizeye, Aline Uwase, Cyprien Munyanshongore, Silvia Franceschi, Gary M. Clifford

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to assess the association between HIV infection and cancer risk in Rwanda approximately a decade after the introduction of antiretroviral therapy (cART). All persons seeking cancer care at Butaro Cancer Center of Excellence (BCCOE) in Rwanda from 2012 to 2016 were routinely screened for HIV, prior to being confirmed with or without cancer (cases and controls, respectively). Cases were coded according to ICD-O-3 and converted to ICD10. Associations between individual cancer types and HIV were estimated using adjusted unconditional logistic regression. 2,656 cases and 1,196 controls differed by gender (80.3% vs. 70.8% female), age (mean 45.5 vs. 37.7 years), place of residence and proportion of diagnoses made by histopathology (87.5% vs. 67.4%). After adjustment for these variables, HIV was significantly associated with Kaposi Sarcoma (n = 60; OR = 110.3, 95%CI 46.8–259.6), non-Hodgkin lymphoma (NHL) (n = 265; OR = 2.5, 1.4–4.6), Hodgkin lymphoma (HL) (n = 76; OR = 5.2, 2.3–11.6) and cancers of the cervix (n = 560; OR = 5.9, 3.8–9.2), vulva (n = 23; OR = 17.8, 6.3–50.1), penis (n = 29; OR = 8.3, 2.5–27.4) and eye (n = 17; OR = 4.7, 1.0–25.0). Associations varied by NHL/HL subtype, with that for NHL being limited to DLBCL (n = 56; OR = 6.6, 3.1–14.1), particularly plasmablastic lymphoma (n = 6, OR = 106, 12.1–921). No significant associations were seen with other commonly diagnosed cancers, including female breast cancer (n = 559), head and neck (n = 116) and colorectal cancer (n = 106). In conclusion, in the era of cART in Rwanda, HIV is associated with increased risk of a range of infection-related cancers, and accounts for an important fraction of cancers presenting to a referral hospital.

Original languageEnglish
Pages (from-to)1348-1355
Number of pages8
JournalInternational Journal of Cancer
Volume143
Issue number6
DOIs
Publication statusPublished - Sep 15 2018

Fingerprint

Rwanda
HIV Infections
Neoplasms
HIV
Non-Hodgkin's Lymphoma
Therapeutics
Hodgkin Disease
Vulva
Kaposi's Sarcoma
Penis
Uterine Cervical Neoplasms
Colorectal Neoplasms
Neck
Referral and Consultation
Logistic Models
Head
Breast Neoplasms

Keywords

  • cancer
  • epidemiology
  • HIV

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mpunga, T., Znaor, A., Uwizeye, F. R., Uwase, A., Munyanshongore, C., Franceschi, S., & Clifford, G. M. (2018). A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. International Journal of Cancer, 143(6), 1348-1355. https://doi.org/10.1002/ijc.31537

A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. / Mpunga, Tharcisse; Znaor, Ariana; Uwizeye, F. Regis; Uwase, Aline; Munyanshongore, Cyprien; Franceschi, Silvia; Clifford, Gary M.

In: International Journal of Cancer, Vol. 143, No. 6, 15.09.2018, p. 1348-1355.

Research output: Contribution to journalArticle

Mpunga, T, Znaor, A, Uwizeye, FR, Uwase, A, Munyanshongore, C, Franceschi, S & Clifford, GM 2018, 'A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda', International Journal of Cancer, vol. 143, no. 6, pp. 1348-1355. https://doi.org/10.1002/ijc.31537
Mpunga, Tharcisse ; Znaor, Ariana ; Uwizeye, F. Regis ; Uwase, Aline ; Munyanshongore, Cyprien ; Franceschi, Silvia ; Clifford, Gary M. / A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. In: International Journal of Cancer. 2018 ; Vol. 143, No. 6. pp. 1348-1355.
@article{30c804758596459d988c46a65f34b0e5,
title = "A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda",
abstract = "The aim of this study was to assess the association between HIV infection and cancer risk in Rwanda approximately a decade after the introduction of antiretroviral therapy (cART). All persons seeking cancer care at Butaro Cancer Center of Excellence (BCCOE) in Rwanda from 2012 to 2016 were routinely screened for HIV, prior to being confirmed with or without cancer (cases and controls, respectively). Cases were coded according to ICD-O-3 and converted to ICD10. Associations between individual cancer types and HIV were estimated using adjusted unconditional logistic regression. 2,656 cases and 1,196 controls differed by gender (80.3{\%} vs. 70.8{\%} female), age (mean 45.5 vs. 37.7 years), place of residence and proportion of diagnoses made by histopathology (87.5{\%} vs. 67.4{\%}). After adjustment for these variables, HIV was significantly associated with Kaposi Sarcoma (n = 60; OR = 110.3, 95{\%}CI 46.8–259.6), non-Hodgkin lymphoma (NHL) (n = 265; OR = 2.5, 1.4–4.6), Hodgkin lymphoma (HL) (n = 76; OR = 5.2, 2.3–11.6) and cancers of the cervix (n = 560; OR = 5.9, 3.8–9.2), vulva (n = 23; OR = 17.8, 6.3–50.1), penis (n = 29; OR = 8.3, 2.5–27.4) and eye (n = 17; OR = 4.7, 1.0–25.0). Associations varied by NHL/HL subtype, with that for NHL being limited to DLBCL (n = 56; OR = 6.6, 3.1–14.1), particularly plasmablastic lymphoma (n = 6, OR = 106, 12.1–921). No significant associations were seen with other commonly diagnosed cancers, including female breast cancer (n = 559), head and neck (n = 116) and colorectal cancer (n = 106). In conclusion, in the era of cART in Rwanda, HIV is associated with increased risk of a range of infection-related cancers, and accounts for an important fraction of cancers presenting to a referral hospital.",
keywords = "cancer, epidemiology, HIV",
author = "Tharcisse Mpunga and Ariana Znaor and Uwizeye, {F. Regis} and Aline Uwase and Cyprien Munyanshongore and Silvia Franceschi and Clifford, {Gary M.}",
year = "2018",
month = "9",
day = "15",
doi = "10.1002/ijc.31537",
language = "English",
volume = "143",
pages = "1348--1355",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - A case–control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda

AU - Mpunga, Tharcisse

AU - Znaor, Ariana

AU - Uwizeye, F. Regis

AU - Uwase, Aline

AU - Munyanshongore, Cyprien

AU - Franceschi, Silvia

AU - Clifford, Gary M.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - The aim of this study was to assess the association between HIV infection and cancer risk in Rwanda approximately a decade after the introduction of antiretroviral therapy (cART). All persons seeking cancer care at Butaro Cancer Center of Excellence (BCCOE) in Rwanda from 2012 to 2016 were routinely screened for HIV, prior to being confirmed with or without cancer (cases and controls, respectively). Cases were coded according to ICD-O-3 and converted to ICD10. Associations between individual cancer types and HIV were estimated using adjusted unconditional logistic regression. 2,656 cases and 1,196 controls differed by gender (80.3% vs. 70.8% female), age (mean 45.5 vs. 37.7 years), place of residence and proportion of diagnoses made by histopathology (87.5% vs. 67.4%). After adjustment for these variables, HIV was significantly associated with Kaposi Sarcoma (n = 60; OR = 110.3, 95%CI 46.8–259.6), non-Hodgkin lymphoma (NHL) (n = 265; OR = 2.5, 1.4–4.6), Hodgkin lymphoma (HL) (n = 76; OR = 5.2, 2.3–11.6) and cancers of the cervix (n = 560; OR = 5.9, 3.8–9.2), vulva (n = 23; OR = 17.8, 6.3–50.1), penis (n = 29; OR = 8.3, 2.5–27.4) and eye (n = 17; OR = 4.7, 1.0–25.0). Associations varied by NHL/HL subtype, with that for NHL being limited to DLBCL (n = 56; OR = 6.6, 3.1–14.1), particularly plasmablastic lymphoma (n = 6, OR = 106, 12.1–921). No significant associations were seen with other commonly diagnosed cancers, including female breast cancer (n = 559), head and neck (n = 116) and colorectal cancer (n = 106). In conclusion, in the era of cART in Rwanda, HIV is associated with increased risk of a range of infection-related cancers, and accounts for an important fraction of cancers presenting to a referral hospital.

AB - The aim of this study was to assess the association between HIV infection and cancer risk in Rwanda approximately a decade after the introduction of antiretroviral therapy (cART). All persons seeking cancer care at Butaro Cancer Center of Excellence (BCCOE) in Rwanda from 2012 to 2016 were routinely screened for HIV, prior to being confirmed with or without cancer (cases and controls, respectively). Cases were coded according to ICD-O-3 and converted to ICD10. Associations between individual cancer types and HIV were estimated using adjusted unconditional logistic regression. 2,656 cases and 1,196 controls differed by gender (80.3% vs. 70.8% female), age (mean 45.5 vs. 37.7 years), place of residence and proportion of diagnoses made by histopathology (87.5% vs. 67.4%). After adjustment for these variables, HIV was significantly associated with Kaposi Sarcoma (n = 60; OR = 110.3, 95%CI 46.8–259.6), non-Hodgkin lymphoma (NHL) (n = 265; OR = 2.5, 1.4–4.6), Hodgkin lymphoma (HL) (n = 76; OR = 5.2, 2.3–11.6) and cancers of the cervix (n = 560; OR = 5.9, 3.8–9.2), vulva (n = 23; OR = 17.8, 6.3–50.1), penis (n = 29; OR = 8.3, 2.5–27.4) and eye (n = 17; OR = 4.7, 1.0–25.0). Associations varied by NHL/HL subtype, with that for NHL being limited to DLBCL (n = 56; OR = 6.6, 3.1–14.1), particularly plasmablastic lymphoma (n = 6, OR = 106, 12.1–921). No significant associations were seen with other commonly diagnosed cancers, including female breast cancer (n = 559), head and neck (n = 116) and colorectal cancer (n = 106). In conclusion, in the era of cART in Rwanda, HIV is associated with increased risk of a range of infection-related cancers, and accounts for an important fraction of cancers presenting to a referral hospital.

KW - cancer

KW - epidemiology

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=85046040653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046040653&partnerID=8YFLogxK

U2 - 10.1002/ijc.31537

DO - 10.1002/ijc.31537

M3 - Article

C2 - 29663358

AN - SCOPUS:85046040653

VL - 143

SP - 1348

EP - 1355

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -